SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-112926
Filing Date
2023-04-24
Accepted
2023-04-24 16:30:54
Documents
12
Period of Report
2023-04-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d470193d8k.htm   iXBRL 8-K 28466
  Complete submission text file 0001193125-23-112926.txt   151692

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tars-20230418.xsd EX-101.SCH 2513
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tars-20230418_lab.xml EX-101.LAB 18067
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tars-20230418_pre.xml EX-101.PRE 11323
6 EXTRACTED XBRL INSTANCE DOCUMENT d470193d8k_htm.xml XML 3474
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 23840473
SIC: 2836 Biological Products, (No Diagnostic Substances)